Key facts
- This page summarizes Hakon Bergheim's Form 4 filing for Adagio Medical Holdings, Inc. (ADGM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Aug 2024, 08:00.
Hakon Bergheim - 31 Jul 2024 Form 4 Insider Report for Adagio Medical Holdings, Inc. (ADGM)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ADGM
- Reported as of
- 31 Jul 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ John Dahldorf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Hakon Bergheim filed Form 4 for Adagio Medical Holdings, Inc. (ADGM) on 02 Aug 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADGM
transaction
Common Stock
Other
- Transaction value
- Shares
- +7,539
- Change %
- Price
- Shares after
- 7,539
- Date
- 31 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADGM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,000
- Change %
- Price
- Shares after
- 1,000
- Date
- 31 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000
- Exercise price
- $9.78
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the business combination (the "Business Combination") contemplated by the Business Combination Agreement (the "BCA"), dated February 13, 2024, as amended, by and among Adagio Medical Holdings, Inc. (formerly known as Aja Holdco Inc., "New Adagio" and following the completion of the Business Combination, the "Issuer"), ARYA Sciences Acquisition Corp IV, Adagio Medical, Inc. ("Adagio") and certain other parties thereto, as described in the Registration Statement on Form S-4 (File No. 333-278811) filed with the U.S. Securities and Exchange Commission ("SEC") and declared effective on July 12, 2024, acquired by the reporting person in exchange for the shares of Adagio common stock held by the reporting person prior to the completion of the Business Combination.
Footnote F2
Pursuant to the BCA, upon the consummation of the Business Combination, the In-the-Money Options (as defined in the BCA) held by the reporting person prior to the completion of the Business Combination were canceled and extinguished in exchange for options to purchase shares of New Adagio Common Stock.
Footnote F3
The options are fully vested; provided, however, that the reporting person may not exercise any of the options until a registration statement on Form S-8 covering the issuance of the options is filed by the Issuer with the SEC and declared effective.